Alec Stranahan
Stock Analyst at B of A Securities
(0.77)
# 3,905
Out of 4,918 analysts
32
Total ratings
40%
Success rate
-25.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVAX Novavax | Maintains: Neutral | $10 → $9 | $6.56 | +37.20% | 4 | Jul 22, 2025 | |
| KRYS Krystal Biotech | Maintains: Buy | $193 → $192 | $156.98 | +22.31% | 4 | Jul 22, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $18.83 | +123.05% | 1 | Mar 28, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Neutral | $14 → $12 | $4.53 | +164.90% | 5 | Mar 5, 2025 | |
| CADL Candel Therapeutics | Initiates: Buy | $15 | $6.29 | +138.47% | 1 | Feb 7, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $6.65 | +276.22% | 4 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $1.95 | +464.10% | 1 | Jan 7, 2025 | |
| ERAS Erasca | Upgrades: Buy | $5 | $1.39 | +259.71% | 2 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $3.68 | +63.04% | 2 | Nov 25, 2024 | |
| EDIT Editas Medicine | Upgrades: Buy | $13 → $15 | $2.44 | +514.75% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $55 | $36.63 | +50.15% | 3 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $7.96 | +427.64% | 1 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $35.02 | -82.87% | 2 | Dec 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $60 → $5 | $0.89 | +464.78% | 1 | Dec 2, 2022 |
Novavax
Jul 22, 2025
Maintains: Neutral
Price Target: $10 → $9
Current: $6.56
Upside: +37.20%
Krystal Biotech
Jul 22, 2025
Maintains: Buy
Price Target: $193 → $192
Current: $156.98
Upside: +22.31%
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $18.83
Upside: +123.05%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $4.53
Upside: +164.90%
Candel Therapeutics
Feb 7, 2025
Initiates: Buy
Price Target: $15
Current: $6.29
Upside: +138.47%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $6.65
Upside: +276.22%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $1.95
Upside: +464.10%
Erasca
Jan 7, 2025
Upgrades: Buy
Price Target: $5
Current: $1.39
Upside: +259.71%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $3.68
Upside: +63.04%
Editas Medicine
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $2.44
Upside: +514.75%
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $36.63
Upside: +50.15%
May 19, 2023
Initiates: Buy
Price Target: $42
Current: $7.96
Upside: +427.64%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $35.02
Upside: -82.87%
Dec 2, 2022
Downgrades: Underperform
Price Target: $60 → $5
Current: $0.89
Upside: +464.78%